Recurrence characteristics and clinicopathological results of borderline ovarian tumors

Abstract

Background This study aimed to investigate the clinical and pathological characteristics, and the recurrence and prognostic factors of borderline ovarian tumors (BOTs). Methods The data of 286 patients admitted to hospital and followed up for more than ten months were analyzed retrospectively to study the clinicopathological characteristics and related factors of recurrence. Results The median age of the patients was 42.06 ± 14.97 years, and the duration of the follow-up ranged from 10–109 months. During the follow-up period, 40 patients had a recurrence. Of these patients, 36 were ≤ 40 years, and patients with premenopausal recurrence accounted for 20.5% (36/176). In patients undergoing conservative treatment or radical operations, the recurrence rates were 21.3% and 1.8%, respectively, and they were 13.4% (36/268) in patients at Federation International of Gynecology and Obstetrics (FIGO) stage I, and 22.2% (4/18) in patients at an advanced stage. Postoperative pathology revealed that 40 patients had micropapillary tumors, among whom ten patients (25%) had a recurrence, and 19 patients had complications with interstitial infiltration. Of these 19 patients, six had a recurrence (31.5%). Another 22 patients had complications with calcified sand bodies; among these, eight patients (36.4%) had a recurrence. All the differences were statistically significant (P < 0.05). There were four cancer-related deaths during the follow-up period. Late FIGO stage, conservative operation, and a high level of carbohydrate antigen 125 (CA125) were independent risk factors for the recurrence of BOTs. Conclusion BOTs usually occur in women under 40 years, have an occult onset, and half of the patients have no obvious clinical manifestations. Serum CA125 level can be used as a tumor marker to detect BOTs and the risk of its recurrence. Operation mode and FIGO stage are important independent factors for the recurrence of BOTs.

Oncologic and reproductive outcomes of fertility-sparing surgery for borderline ovarian tumors: First presentation of 10-year experience from a Serbian referral center

“…The recurrence rate of 7.7% is comparable to the commonly reported recurrence rate following radical surgical treatment of stage I BOT, which is 5% [6]. Moreover, it was somewhat lower than the recurrence rate after FSS described in other investigations (13.4%) [18]. All examined patients with subsequent recurrences primarily underwent USOE.…”

The value of ultrasonography combined with carbohydrate antigen 125 and 19-9 detection in the diagnosis of borderline ovarian tumors and prediction of recurrence

“…For patients with these characteristics, it is recommended to undergo comprehensive staged surgery and enhanced follow-up. The CA 125 level can be adopted as a screening and postoperative review monitoring index for patients with BOTs, and great importance should be attached to patients with elevated CA 125 levels ( 18 , 19 ).…”

Predictive features of borderline ovarian tumor recurrence in patients with childbearing potential undergoing conservative treatment

“…In the literature, conflicting results were reported on the prognostic impact of tumor size in BOT patients (20). Recently, Niu et al (3), in a retrospective analysis including both conservative and radical treatment, recognized the ovarian tumor size at diagnosis as associated with increased Ca125 level and recurrence events in BOT cases. Furthermore, in a large prospective study by Kobayashi et al (21) involving 6398 Japanese women with an initial diagnosis of endometrioma, the tumor diameter was also an independent risk factor for developing ovarian cancer.…”

“…Borderline ovarian tumors (BOT) represent 10-12% of ovarian cancers with a higher prevalence in young patients (1). An incidence of 4.8 new cases per 100.000 women is reported in Europe (2) with a 13.9% relapse rate in comprehensive surgical treatment cases (3). International guidelines recommend unilateral salpingo-oophorectomy and multiple peritoneal biopsies in patients with childbearing potential who wish to maintain their fertility (4).…”